Cirius Therapeutics Inc. (previously Octeta Therapeutics LLC) completed a series A financing of up to $40 million – drawing down $30 million in the initial tranche, according to an SEC filing – in a round that was co-led by Frazier Healthcare Partners and Novo A/S.